As shown by Parmenter and colleagues,21 CCL20 expression was significantly downregulated in a panel of oncogenic BRAF(V600) mutation-harbouring melanoma cell lines in response to treatment with the BRAF inhibitor vemurafenib (Fig. S3A). The gene discussed is CCL20; the disease is melanoma.